02:34 , Feb 26, 2019 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method for making iPS cells hypoimmunogenic could be used to generate allogeneic cell grafts for transplant therapies. The method involves two to three steps: simultaneous or sequential CRISPR-Cas9 (CRISPR-associated protein 9)-mediated...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
13:36 , Sep 14, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2017

New Therapeutic Targets and Biomarkers: August 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during August 2017. Therapeutic targets are defined as any protein, gene or other...
19:27 , Sep 11, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Poly(amine-co-ester) nanoparticles could be used to deliver therapeutic nucleic acids to prevent transplant rejection. The method involves pre-transplant, ex vivo treatment of donor tissue with poly(amine-co-ester) nanoparticles loaded with therapeutic nucleic acids. In...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

University of Maryland Baltimore County other research news

University researchers published in the Proceedings of the National Academy of Sciences the ability of tumor cells transfected with major histocompatibility complex (MHC) class II genes to present endogenous antigen and induce tumor-specific immunity. Expression...
08:00 , Mar 27, 2000 |  BC Week In Review  |  Company News

Antigen Express Inc. other research news

Antigen Express received a $173,000 Phase I SBIR grant from the National Cancer Institute to develop a colon cancer vaccine using cancer cells transfected with the MHC Class II transactivator gene (CIITA) and an antisense...